latacomp 50 mikrog/ml+5 mg/ml øjendråber, opløsning
ratiopharm gmbh - latanoprost, timololmaleat - øjendråber, opløsning - 50 mikrog/ml+5 mg/ml
oxaliplatin "fresenius kabi" 5 mg/ml koncentrat til infusionsvæske, opløsning
fresenius kabi ab - oxaliplatin - koncentrat til infusionsvæske, opløsning - 5 mg/ml
pemetrexed "reig jofre" 100 mg pulver til koncentrat til infusionsvæske, opløsning
laboratorio reig jofre s.a. - pemetrexeddinatrium - pulver til koncentrat til infusionsvæske, opløsning - 100 mg
levetiracetam "accord healthcare" 100 mg/ml oral opløsning
accord healthcare b.v. - levetiracetam - oral opløsning - 100 mg/ml
levetiracetam "aristo pharma" 100 mg/ml oral opløsning
aristo pharma gmbh - levetiracetam - oral opløsning - 100 mg/ml
dorzolamid/timolol "teva" 20+5 mg/ml øjendråber, opløsning
teva b.v. - dorzolamidhydrochlorid, timololmaleat - øjendråber, opløsning - 20+5 mg/ml
pemetrexed "reig jofre" 500 mg pulver til koncentrat til infusionsvæske, opløsning
laboratorio reig jofre s.a. - pemetrexeddinatrium - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
travoprost/timolol "stada" 40 mikrog/ml+5 mg/ml øjendråber, opløsning
stada arzneimittel ag - timololmaleat, travoprost - øjendråber, opløsning - 40 mikrog/ml+5 mg/ml
cabazitaxel "zentiva" 20 mg/ml koncentrat til infusionsvæske, opløsning
zentiva k.s. - cabazitaxel - koncentrat til infusionsvæske, opløsning - 20 mg/ml
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.